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Abstract
Background: The pharmacokinetics (PKs) and pharmacodynamics (PDs) of telmisartan varies among the individuals, and the
main causes remain unknown. The aim of this study was to evaluate the impact of ORM1, as well as ABCC2, ABCB1, ABCG2
and SLCO1B3 polymorphisms, on the disposition of the drug and BP change after taking 40 mg telmisartan in 48 healthy
Chinese males.
Method: A total of 48 healthy males were included in this trial. Every volunteer ingested a single dose of 40 mg telmisartan,
and the plasma drug concentration and blood pressure (BP) were measured up to 48 h.
Result: In this study, the area under the plasma concentration-time curve (AUC) in the heterozygotes of ORM1 113AG was
higher than that in the wild-type homozygotes, AUC(0–48) (113AA vs. 113AG, 1,549.186859.84 ng?h/ml vs.
2,313.5461,257.71 ng?h/ml, P = 0.033) , AUC( 0 – ‘ ) (113AA vs. 113AG, 1,753.1361,060.60 ng?h/ml vs.
2,686.9061,401.87 ng?h/ml, P = 0.016), and the change(%) of the diastolic blood pressure (DBP) from the baseline BP
value also showed a significant difference between the ORM1 113AG and 113AA genotypes at 5 h after taking telmisartan
(P = 0.026). This study also showed that the allele of ABCC2 C3972T would affected the disposition of telmsiartan and the
DBP change significantly after taking the drug. However, the common SNPs of ABCG2 C421, ABCB1 C3435T, and SLCO1B3
T334G showed no impacts on the PKs of telmisartan or BP change(%) in our trial.
Conclusion: The ORM1 A113G polymorphism was associated with the PKs variability after taking telmsiartan, as well as
ABCC2 C3972T. The heterozygotes of ORM1 113AG showed a larger AUC and a notable BP change(%) from the baseline
compared with the wild-type.
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Introduction
There are about 1 billion hypertension patients worldwide and
the number is still sharply increasing. Effective use the antihyper-
tensive agents has become a particular challenge for the public
health, as the blood pressure (BP)-lowering responses is diverse and
hard to predict in individuals [1]. Telmisartan is a highly selective
antagonist for the angiotensin II receptor type 1, and has the
unique pharmacological properties characterized by its long
duration of action and increased the tolerability. Telmisartan is
equivalent to ramipril in the patients with vascular disease or high-
risk diabetes occurred and associated with less angioedema [2].
In the healthy volunteers and hypertensive patients, a remark-
able inter-individual variability had been reported with the peak
concentration in plasma (Cmax) and the area under the plasma
concentration-time curve (AUC) of telmisartan [3–6]. Further-
more, it has been reported that after a high dose of telmisartan, the
drug was eliminated faster in Caucasian than in Chinese [4–5],
suggesting that an ‘‘ethnic’’ difference was existed in the drug’s
disposition with unknown mechanism, while another population
pharmacokinetics study of telmisartan suggested that the ‘‘race
difference’’ was not large [6]. There were a few studies focused on
the pharmacogenetics of telmisartan, however, the discoveries
contributed little to the variability of pharmacokinetics (PKs).
Telmisartan was not metabolized by the cytochrome P450 system,
and almost all of the drug was excreted as the unchanged parent
drug into the feces [7]. Thus, the variability of the pharmacoki-
netics (PKs) of telmisartan may occur in the absorption,
distribution, or excretion processes.
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When administrated orally, telmisartan shows an absolute
bioavailability of 43%, a long elimination half-life of almost
24 h, and more than 99.5% of telmisartan binds to the plasma
proteins [8]. Telmisartan displays a saturable binding to the alpha-
1-acid glycoprotein 1 (AAG1; encoded by ORM1) in addition to
the human serum albumin [9]. The AAG is a major binding
protein in plasma for various basic drugs, and is encoded by 2 loci,
i.e., ORM1 and ORM2, and the content of ORM1 is dominant.
Unlike ORM2, ORM1 is highly polymorphic [1]. There are 3
common haplotypes present at the ORM1 locus (ORM1*F1 has
113A/520G; ORM1*F2 has 113A/520A and ORM1*S has 113G/
520G) [10,12]. Recent investigations suggested that the ORM1 *S
genotypes had a stronger binding force to the drugs, such as
quinidine, disopyramide and nortriptyline, thus the *S alleles may
decreased the concentrations of the free drugs in the serum
[11,13]. And it’s reported that the allele of 520A was rare in Asia
[10,11], and the minor allele frequency (MAF) is 0.03% in Asia
(data from hapmap), which supported that the haplotype of *F2
may also rare [12,15]. Meanwhile, our institute previous
researches found that the alleles of ORM1 A113G can significantly
affect the disposition of the drugs, nortriptyline and warfarin (data
wasn’t published).
The multidrug-resistance protein 2 (MRP2, encoded by
ABCC2), is a member of the ATP-binding cassette transporters
family and plays a dominant role in the transport of various drugs,
including telmisartan [6,17–18]. ABCC2 was highly polymorphic,
and it was reported that three common SNPs C-24T, G1249A and
C3972T [19,25] were in linkage disequilibrium and likes to
decrease the transporter function probably by a posttranscriptional
modification on transporter protein expression [19,20]. It was
reported that ABCC2 C-24T altered the pharmacokinetics of
various drugs, including irinotecan, SN-38 and mycophenolic acid
[21,22]. However, some other studies found that ABCC2 C-24T
polymorphism can’t alter the drug’s transport [26]. Besides
MRP2, some other transporters also participated in the disposition
of telmisartan, such as the multiple drug resistance-1 protein
(MDR1, encoded by ABCB1), including the human breast cancer
resistance protein 2 (BCRP2, encoded by ABCG2), and the influx
pump of the human organic anion transporting polypeptide 1B3
(OATP1B3, encoded by SLCO1B3) [16,27–30]. For MDR1, the
polymorphism C3435T on exon 26 as a silent mutation, would
affect the expression level and transfer functions [18], even affect
the concentration of the substrates via absorption or excretion. It
also has been suggested that the ABCG2 C421A may affect the
protein expression, membrane surface translocation, efflux activ-
ity, or ATPase activity [24]. It was reported that the patients with
C421A mutation achieved a higher plasma drug levels, suggesting
a significant reduction in BCRP2 mediated excretion [23],even
affected the drug’s response [24]. And the previous reports had
shown that the common polymorphisms T334G on SLCO1B3 may
alter the transporter’s activity in vitro and vivo [31], then alter the
pharmacokinetic profile of the drugs, such as mycophenolic acid,
rosuvastatin [31].
In this study, we intend to investigate the impacts of the
polymorphisms of ORM1, ABCC2, ABCB1, ABCG2, and SLCO1B3
on the PKs and the BP change after taking the drug.
Methods
The protocol for this trial and supporting TREND checklist are
available as supporting information; see Checklist S1 and Protocol
S1.
Subjects and Study Design
A total of 48 unrelated Chinese healthy males from Changsha
city were enrolled in this clinical trial between May 2010 and Dec
2010. The subjects were excluded if they had a history or evidence
of hepatic, renal, gastrointestinal, or hematologic abnormalities;
any other acute or chronic disease; or an allergy to any drug. No
medications, herbal medicines, alcohol, citrus juices, or beverages
containing caffeine were permitted during the study. The mean
age of the subjects was 22.8362.51 y (range 19,34 y), the mean
weight was 63.3367.75 kg (range 49,78 kg), and the mean
height was 171.5765.22 cm (range 162,183 cm) (Table 1, Table
S1).
The study protocol was approved by the Ethical Committee of
the Institute of Clinical Pharmacology, Central South University.
The registration number (ChiCTR-TNC-10000898) and the trial
protocol were validated in the Chinese Clinical Trial Registry.
The trial was carried out in the institute of Clinical Pharmacology,
Changsha, Hunan, China. Written informed consent and the
clinical characteristics were obtained from each subjects before the
trial. Each of the volunteers ingested a single tablet of a 40 mg
dose of telmisartan (Micardis; Boehringer Ingelheim International
GmbH, Ingelheim, Germany) with 200 mL water at 08:00. The
subjects received a standardized breakfast 2 h after the adminis-
tration of telmisartan, and received a warm meal at 12:00 and
supper at 18:00. Five milliliters of the venous blood samples were
drawn into EDTA tubes at 0 (before administration), 0.25, 0.5,
0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, and 48 h after
administration. The sitting BP of each participants were measured
twice using a mercury manometer at 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11, 12, 24, 48 h after administration. The plasma was separated
by centrifugation at 30006g for 15 min and stored at 220uC until
extraction and analysis. The DNA was extracted through the
standard phenol-chloroform extraction method.
PKs and BP Change(%) from the Baseline
The PKs of telmisartan were characterized by Cmax, Tmax, T1/2,
AUC(0–48), and AUC(0–‘). The elimination rate constant (ke) was
determined by linear regression analysis of the log-linear part of
the elimination phase of the concentration-time curve. The T1/2
was calculated by the equation T1/2 = ln2/ke. The AUC(0–‘) was
calculated by the combination of the linear and log-linear
trapezoidal rules, with extrapolation to infinity by division of the
last measured concentration by ke. The CL/F was calculated with
the quotation CL/F = Pxo/AUC(0–‘), where Pxo represents the
administration dose [15;16]. The BP change (%) from the baseline
was calculated using the equation (BP - BP0)/BP06100%, which
BP0 represents the BP before the drug administration.
Genotyping
The alleles of ORM1 A113G were determined by a PCR-RFLP
procedure as described below. The primers for ORM1 A113G
were 59-GAACTGAATCTATGTTTGTCTTCC-39 (Forward)
and 59-CGACCACAGCCAGCAGGG-39 (Reversed) and the
endonuclease enzyme was EconI. For there is a high degree of
homology between ORM1 and OMR2, then we took the PCR
product sequencing, and verified that the PCR products were
belong to ORM1 but not ORM2 gene. ABCC2 C-24T SNPs was
detected by pyro-sequencing (Pyromark Q96 ID System, Qiagen,
Germany). The forward primer was 59-GGCAAGGTTAAC-
GATTAAATGG-39; the reverse primer was 59-GCA-
GAACTTCTCCAGCATGAT-39 (with 59-biotin), and the se-
quencing primer was 59-TCATATTAATAGAAGAGTCT-39.
We determined the ABCG2 C421A alleles by direct sequencing.
The forward primer was 59-ACTGCAGGTTCATCATCAT-
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TAGCTAGA-39, and the reverse primer was 59-
CCGTTCGTTTTTTTCATGATTC-39. Genotyping the ABCB1
C3435T as the method reported [33]. The genotypes of ABCC2
C3972T, ABCC2 G1249A, and, SLCO1B3 T334G were deter-
mined by a PCR-RFLP procedure as described in previous
reports. The primers for ABCC2 C3972T were 59-
GTGGACTGTTCGGCTGAGTT-39 (Forward) and 59-
TCACTCCACCTACCTTCTCCATG-39 (Reversed) and the
endonuclease enzyme was Bsh1285I. The primers for ABCC2
G1249A were 59-GGGCAAAGAAGTGTGTGGAT-39 (For-
ward) and 59-TGGGATTACAAGCACCATCA-39 (Reversed)
and the endonuclease enzyme was NcoI. The primers for SLCO1B3
T334G were 59-GAAGGTACAATGTCTTGGGC-39 (Forward)
and 59-CTCTCAAAAGGTAACTGCCC-39 (Reversed) and the
endonuclease enzyme was Alu I.
The Linkage Disequilibrium Analysis
The linkage disequilibrium analysis of the ABCC2 variants (C-
24T, G1249A and C3972T) was constructed using the online
software SHEsis (http://analysis2.bio-x.cn/my Analysis.php).
Measurement of the Plasma AAG1 level
The concentration of AAG1 was determined using a commer-
cial ELISA kit (ab108852, ABCAM, Cambridge, UK) for the
quantitative determination according to the instruction by the
manufacturer. The detection linearity of this kit was from 3.13 to
200 ng/ml. The plasma samples were diluted 1:25000 with the
diluted buffer. Absorbance values were read at 450 nm on the
multimode ELISA reader (Beckman Coulter, Miami, FL, USA).
Determining the Concentration of Telmisartan in Plasma
A Waters Alliance 2695 liquid chromatographic system (Waters,
Milford, MA, USA) equipped with a HyPurity C18 column
(2.1 mm6150 mm, 5 mm; Thermo Hypersil-Keystone, America)
was used to determine the concentration of telmisartan in the
plasma. The column temperature was 40uC. The mobile phase
consisted of acetonitrile and 5 mM ammonium acetate (containing
0.1% acetic acid) at a ratio of 45:55 (v: v), and the flow rate was
0.3 mL/min. Irbesartan (100 ng/mL) was used as the internal
standard. Fifty microliters of irbesartan and 400 mL of acetonitrile
were added into 180 mL of plasma. After mixing on a vortex mixer
for 5 min and waiting for 10 min, the mixture was then
centrifuged at 15000 rpm for 5 min. A total of 200 mL of
supernatant was put into an injection tube, and an aliquot of
5 mL of supernatant in tubes was injected into the HPLC system
each time. Mass spectrum (MS) detection was performed on a
Waters Quattro Micro API mass spectrometer (Waters, Milford,
MA, USA). For telmisartan and irbesartan, the precursor-to-
production reactions monitored were m/z 515 to 429 and m/z
428 to 207, respectively. The range of quantification for
telmisartan in the plasma was 5 ng/mL to 1000 ng/mL, and
the inter-day and intraday precisions for all analyses were less than
15% (coefficient of variation).
Statistical Analyses
All results were expressed as mean 6 SD in the text and tables
and, for clarity, as mean 6 SEM in the figures. Statistical
significance of the difference was evaluated using SPSS statistical
software (SPSS Inc., ver.18.0). A P value of ,0.05 was considered
to be statistically significant. The contribution of the multiple
factors to the variability of the parameters was evaluated using the
stepwise linear regression analysis, and those variables with
significant P value in the models were shown. The x2 test was
used to test whether the distribution met the Hardy-Weinberg
equilibrium. Statistical comparison of the PKs parameters
including Cmax, AUC(0–48), and AUC(0–‘) among non-carriers,
heterozygous, and homozygous carriers was done by ANOVA
after data points were naturally log-transformed, while CL/F was
analyzed directly through ANOVA. When the P value was
significant, a Tukey HSD test was followed to analysis the
distribution between each two groups. The distribution of the
Tmax and T1/2, among the different genotypes were analyzed by
the Kruskal-Wallis test. Repeated-measure ANOVA (genotypes6
time) with Greenhouse-Geisser correction, and the Tukey tests for
post-hoc multiple comparisons were used to compare the BP
change(%) from the baseline BP value.
Results
Genotyping
Of these 48 subjects, we detected the polymorphisms of ORM1
A113G and the genotypes of ABCC2, ABCB1, ABCG2, and
SLCO1B3, and the frequencies of each genotype was shown in
Table 2. The distributions of all the alleles in this population met
the Hardy-Weinberg equilibrium. The linkage disequilibrium
among the ABCC2 single nucleotide polymorphisms (SNPs) was
analyzed, and the results showed that the alleles of ABCC2
C3972T was mostly in a linkage with ABCC2 C-24T (D9 = 0.997,
r2 = 0.031), and the D9 value was 0.793 and r2 = 0.606 when the
analysis tested between the SNPs of ABCC2 G1249A and C-24T.
Telmisartan PKs and BP Change(%) from the Baseline
After an oral dose of 40 mg telmisartan, the mean AUC
from 0 to 48 h (AUC(0–48)) in 48 healthy males was
1,793.7561,065.94 ng?h/mL, the AUC from 0 to infinity
(AUC(0–‘)) was 2,048.2361,251.07 ng?h/mL, the Cmax was
2,61.156165.42 ng/mL, time to Cmax (Tmax) was
1.2860.54 h, elimination half-life (T1/2) was 17.1568.83 h, and
the clearance (CL/F) was 27.88619.10 L/h. The PK parameters
of telmisartan varied significantly in inter-individuals, for example,
the AUC(0–48), AUC(0–‘), Cmax, Tmax, T1/2, and CL/F of
telmisartan varied 3.9-, 14.5-, 17.8-, 6.0-, 7.6-, and 14.5-folds,
respectively. After taking 40 mg telmisartan, the BP values of the
participants declined lasted for more than 12 h, compared with
the basal BP values. The decline degree of the BP was more
notable in DBP than SBP, and the most significantly declined DBP
Table 1. The demographics information of the participants.

















BMI, body mass index.
doi:10.1371/journal.pone.0070341.t001
Pharmacogenomics Research on Telmisartan
PLOS ONE | www.plosone.org 3 August 2013 | Volume 8 | Issue 8 | e70341
occurred at 3,9 h (Table 3, Figure 1, 2) when measured the BP
change(%) from the baseline up to 48 h.
The Plasma AAG1 Concentration Level
There was no significant difference of the plasma AAG1
concentration in different ORM1 genotypes (P = 0.801), the
concentration of AAG1 in individual with ORM1 113AA was
444.256112.86 ng/ml (range 264.17,700.83 ng/ml), and the
concentration in ORM1 113AG was 452.926133.05 ng/ml (range
240.83,738.33 ng/ml).
Association between the ORM1 Genotypes and
Telmisartan PKs and BP Change(%) from the Baseline
As shown in Figure 1 and Table 4, the subjects with ORM1
113AG had a higher AUC compared with the wild-type ORM1
113AA genotype, AUC(0–48) (AA vs. AG, 1,549.186859.84 vs.
2,313.5461,257.71 ng?h/ml, P = 0.033), AUC(0–‘) (AA vs. AG,
1,753.1361,060.60 vs. 2,686.9061,401.87 ng?h/ml, P = 0.016).
The results of the repeated measure ANOVA which corrected by
Greenhouse-Geisser showed that the ORM1 A113G alleles had no
significant impacts on the BP change(%) from the baseline after
taking 40 mg telmisartan. While we found that the subjects with
the genotype of ORM1 113AG appeared to have a more apparent
BP change compared with the wildtype, although the P value was
not significant except the DBP change(%) 5 h (P = 0.026) after
administration (Figure 1, Table 3). There was no significant
difference in the Cmax, CL/F, and T1/2 between the ORM1
genotypes after taking 40 mg telmisartan (Table 4).
Association between the Transporters Gene
Polymorphisms and Telmisartan PKs and BP Change(%)
from the Baseline
The parameters of AUC(0–48), Cmax, CL/F in the different
ABCC2 C3972T genotypes varied significantly (P = 0.031, 0.001,
and 0.001, respectively) (Figure 2, Table 4); The repeated measure
ANOVA results showed that ABCC2 C3972T polymorphism
would significantly affected the DBP change(%) from the baseline
after taking telmisartan(P = 0.018) (Table 5). The DBP change(%)
from the baseline varied significantly at 3, 5, 8, 9 h (P = 0.05,
0.013, 0.026 and 0.010 respectively) among the ABCC2 C3972T
genotypes(Figure 2, Table 3). The Cmax and CL/F of the different
ABCC2 C-24T genotypes also manifested a remarkable difference
(P = 0.008 and 0.005, respectively)(Table 4). In this study, the
polymorphisms of ABCC2(G1249A), ABCB1 (C3435T), SLCO1B3
(T334G) and ABCG2 (C421A) had no significant influence on the
PKs of telmisartan and the BP change(%) from the baseline after
taking telmisartan (Table 3, 4, 5).
Stepwise Regression Analysis
The stepwise multiple regression analysis results showed that the
AUC variability of telmisartan was affected by the polymorphisms
of ORM1 A113G (P = 0.028) and ABCC2 C3972T (P = 0.031). In
this stepwise multiple regression models, we correct the multiple
factors Age, BMI, and basal BP values. The genetic polymor-
phisms ORM1 A113G*ABCC2 C3972T contributed R2 = 0.150
and 0.153 respectively to AUC(0–48) and AUC(0–‘). The ORM1
A113G*ABCG2 C421A contributed R2 = 0.160 to the DBP 5 h
change(%) from the baseline. There was no genetic variants
contributed significantly to Cmax, CL/F, T1/2 and SBP 5 h
change (%) from the baseline (Table 6).
Discussion
In this study, we for the first time reported that the
polymorphism of ORM1 A113G was associated with the variability
of the drug AUC and BP change(%) from the baseline after taking
40 mg telmisartan in Chinese healthy males. The content of the
plasma AAG1 had no significant difference between ORM1
genotypes, while the heterozygotes of ORM1 113AG demonstrated
a higher AUC of the drug and a apparent BP decline after taking
40 mg telmisartan. This result was consistent with the previous
reports that the ORM1 variants can affect the disposition of the
drug, alter the concentrations of the free drugs in the serum [11–
14]. It was reported that there were 7 drug-protein binding sites
with different affinities on the AAG surface, and more binding sites
on the AAG surface with ORM1 113G than ORM1 113A, thus the
affinity was much stronger in the former haplotype [2,32]. The
more drugs bind to plasma proteins, the fewer drugs would be
excreted; and more stored bound-drugs would transformed into
the plasma free drug. Thus the total plasma drug concentration
and AUC in ORM1 113AG heterozygote would be remains in a
higher level. We can speculate that when the drug was in a high
plasma concentration for a long duration of time, the substrate
would manifest as a stronger pharmacodynamics. In our study,
when compared with the wild-type ORM1 113AA, the ORM1
Table 2. Summary of Genetic Variations of SNPs in this Study.
Genes RS No.
Nucleotide
substitution Location Amino Acids MAFa (CHB) MAFa (ASW) MAFa (CEU) MAFb (CHB)
ORM1 rs17650 A113G Exon Gln/Arg 0.275[37] N/A N/A 0.208
ABCC2 rs717620 C-24T 59UTR – 0.201 0.035 0.181 0.281
rs3740066 C3972T Exon Ile/Ile 0.267 0.331 N/A 0.250
rs2273697 G1249A Exon Val/Ile 0.106 0.243 0.132 0.083
ABCB1 rs1045642 C3435T Exon Ile/Ile 0.374 0.205 0.571 0.375
SLCO1B3 rs4149117 T334G Exon Ala/Ser 0.266 0.518 0.143 0.354
ABCG2 rs2231142 C421A Exon Gln/Lys 0.292 0.044 0.111 0.219
adata published on hapmap; b, data calculated in this study, N = 48; N/A, no data found in hapmap.
MAF: Minor Allele frequencies; CHB: Han Chinese in Beijing, China; ASW: African ancestry in Southwest USA; CEU: Utah residents with Northern and Western European
ancestry from the CEPH collection ORM1, orosomucoid 1; ABCC2, ATP-binding cassette, sub-family C, member 2; ABCG2, ATP-binding cassette, sub-family G, member 2;
ABCB1, ATP-binding cassette, sub-family B, member 1; SLCO1B3, solute carrier organic anion transporter family, member 1B3; SNP, single nucleotide polymorphisms;
AUC(0–48) the area under the plasma concentration-time curve (AUC) from 0 to 48 h; AUC(0–‘), AUC from 0 to ‘; Cmax, the peak concentration in plasma; CL/F, clearance;
T1/2, elimination half-life; Tmax, the time to Cmax.
doi:10.1371/journal.pone.0070341.t002
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113AG genotype decrease the basal BP more markedly at 5 h after
taking the drug (SBP, P value = 0.180; DBP, P value = 0.026). The
same tendency of BP change(%) from the baseline between 113AA
and 113AG genotype was also presented in the other time points,
although the P value were not significant (Table 3). The difference
of BP change between the ORM1 genotypes was not as significant
as the PKs, the reasons may be there were many physical,
condition or mental factors would influence the BP. In this
research, the significant difference of drug concentration between
ORM1 genotypes were in 1,4 h after the drug administration,
while the most significant difference of DBP change(%) from the
baseline occurred in 3,9 h. It seemed that the BP change was
lagged behind the PKs several hours. We speculated that because
the ORM1 mostly affected the distribution phase of the drugs
rather than the other disposition phase. So the significant
difference caused by ORM1 polymorphisms may occurred in an
earlier period of drug disposition(1–4 h, in Figure 1), and the
previous researches found that after administering 3 h later, the
BP started to decline, so the BP change seemed to be lagged.
The difference of BP change(%) from the baseline among
ABCC2 C3972T three genotypes was manifested in a concentra-
tion-dependent fashion. After administering 40 mg telmisartan,
the heterozygotes of ABCC2 39732CT showed the lowest AUC,
Cmax, and displayed the minimum SBP and DBP change(%) from
the baseline, while the genotype TT manifested as the highest
AUC, Cmax, and the maximum change of the BP. The significant
difference of DBP change among ABCC2 3972 genotypes occurred
at 3, 5, 8 and 9 h after taking telmisartan(Table 3). For ABCC2
C3972 and C-24T in a strong linkage disequilibrium, our research
was consistent to the previous reports that the Cmax of telmisartan
in the 224CT genotype group was significantly greater than that
in the 224CC genotype (P = 0.0094) in Japanese renal transplant
patients (3). While, the impacts of ABCC2 C3972T polymorphism
on PKs and BP chang(%) from the baseline were not consistent
with the gene-dose effect, the possible reasons may be two. On the
one hand, as ABCC2 C-24T, C3972T, and G1249A SNPs were in
a strong linkage disequilibrium, thus the other two SNPs might
interfere with C3972T to affect the variability of PKs/PDs. It has
been reported that the MRP2 transport function may be affected
by the ABCC2 polymorphisms in a haplotype-dependent mod-
el(33). And besides this three SNPs, some unknown SNPs may also
participated in the disposition of telmisartan and may interacted
Figure 1. The impacts of ORM1 genotypes on the PKs and BP change(%) after 40 mg telmisartan. A, Concentration; B, AUC(0–‘); C, SBP
change(%) from the baseline; D, DBP change(%) from the baseline.
doi:10.1371/journal.pone.0070341.g001
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with ABCC2 C3972T, which need a further research. On the other
hand, only 2 subjects carried the genotype of ABCC2 3972TT
participated in this study, thus the parameters of this two subjects
may won’t reflect the population characteristics of the homozygote
group. This results need confirmed in a more large population.
The underlying mechanisms of telmisartan PKs and PDs highly
varied among the individuals still remain unknown. There were a
few pharmacogenomics studies on telmisartan’s disposition, while
the research results contributed little to the variability [34]. Some
other studies reported that genetic factors, such as ABCB1
C3435T, SLCO1B3 T334G and other related polymorphisms,
showed no influence on the PKs variability [6,34–36]. In our trial,
we confirmed that the polymorphisms of SLCO1B3 T334G,
ABCB1 C3435T, ABCG2 G421A had no significant influence on
telmisartan disposition. It was reported that the haplotype of
UGT1A3*4a can influence the telmisartan’s PKs [35]. The
previous reports also showed that CL/F of telmisartan was
associated with age, dose, gender, alcohol consumption, race and
liver function [6], but in our study the factor of age was
nonfunctional. It was also manifested in our study that the DBP
decline was stronger than SBP after taking telmisartan (Table 3),
which implied that telmisartan would be an ideal choice for the
hypertensive with a higher DBP value.
In our study, all the frequencies of the 7 SNPs in the 48
participates was consistent with the reported frequencies in CHB
population. As reported in the literatures, Mastana found that
there was a significant clinical decrease of the ORM1*S allele
frequency from West to East (r = 0.80, P,0.01) in 48 populations,
Figure 2. The impacts of ABCC2 genotypes on the PKs and BP change(%) after 40 mg telmisartan. A, Concentration; B, AUC(0–‘); C, SBP
change(%) from the baseline; D, DBP change(%) from the baseline.
doi:10.1371/journal.pone.0070341.g002
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Table 4. Telmisartan PKs of 48 health males with different genotypes.
Gene SNPs Genotype AUC(0–48)(ng?h/ml) AUC(0–‘) (ng?h/ml) Cmax(ng/ml) CL/F(l/h) T1/2 (h)
ORM1 A113G AA (28) 1,549.186859.84 1,753.1361,060.60 246.876156.93 32.38621.43 15.6365.09
AG (20) 2,313.5461,257.71 2,686.9061,401.87 293.006184.06 18.6368.74 20.01612.81
P VALUE 0.033* 0.016* 0.289 0.355 0.113
ABCC2 C3972T CC (26) 1,871.186817.89 2,090.836952.69 313.326172.05 18.80610.32 15.8364.11
CT (20) 1,289.896506.60 1,526.476626.97 176.486106.47 10.5966.39 20.09613.27
TT (2) 1,973.906135.44 2,057.50697.27 548.22612.93 32.8960.78 12.2663.11
P VALUE 0.031* 0.105 0.001** 0.001** 0.321
CC vs. CT 0.035* 0.105 0.005** 0.008** 0.476
CC vs.TT 0.896 0.964 0.243 0.083 0.237
CT vs. TT 0.311 0.526 0.014* 0.004** 0.147
ABCC2 C-24T CC (24) 1,809.426843.05 2,017.046976.09 306.166182.01 18.37610.92 15.6164.19
CT (21) 1,348.936525.05 1,588.646637.52 191.526112.96 25.10610.75 19.98612.95
TT (3) 2,214.176427.04 2,411.886617.65 467.576139.99 17.2463.89 14.6264.65
P VALUE 0.060 0.161 0.008** 0.005** 0.523
ABCC2 G1249A GG(41) 1597.796667.24 1832.016790.09 256.456156.87 15.3969.41 18.0169.84
GA(6)+AA(1) 1998.4461108.08 1232.576992.12 355.016236.12 21.30614.17 14.0964.01
P VALUE 0.285 0.417 0.296 0.296 0.614
ABCG2 C421A CC (30) 1,579.226713.71 1,800.866797.05 258.146165.95 15.4969.96 17.69610.97
CA (15) 1,679.296719.04 1,840.076798.27 297.906170.29 17.87610.22 16.34611.36
AA (3) 1,943.436921.94 2,459.6861,394.14 186.586133.13 19.5768.94 20.7565.44
P Value 0.669 0.573 0.481 0.540 0.265
ABCB1 C3435T CC (20) 1,606.836646.33 1,791.716814.66 237.236126.55 14.2367.59 15.4865.05
CT (20) 1,673.536789.53 1,920.076849.29 291.526206.17 17.49612.37 18.95612.29
TT (8) 1,598.626913.64 1,846.3061,026.48 274.706165.31 16.4869.92 18.6768.88
P VALUE 0.587 0.317 0.951 0.984 0.076
SLCO1B3 T334G GG (18) 1,702.256740.60 1,877.336806.34 298.076204.22 17.88612.25 15.9064.08
GT (26) 1,574.476755.06 1,829.076896.92 232.816132.75 13.9767.97 18.56611.78
TT (4) 1,704.896797.20 1,914.586939.86 338.566196.27 25.38613.32 17.3168.43
P VALUE 0.793 0.929 0.424 0.307 0.994
Data were shown as mean6SD;
*P,0.05; **P,0.01.
PKs, pharmacokinetics; ORM1, orosomucoid 1; ABCC2, ATP-binding cassette, sub-family C, member 2; ABCG2, ATP-binding cassette, sub-family G, member 2; ABCB1, ATP-
binding cassette, sub-family B, member 1; SLCO1B3, solute carrier organic anion transporter family, member 1B3; SNP, single nucleotide polymorphisms; AUC(0–48) the
area under the plasma concentration-time curve (AUC) from 0 to 48 h; AUC(0–‘), AUC from 0 to ‘; Cmax, the peak concentration in plasma; CL/F, clearance; T1/2,
elimination half-life; Tmax, the time to Cmax.
doi:10.1371/journal.pone.0070341.t004
Table 5. The significance affected by time or genotypes on the BP change(%) from the baseline.
SBP change (%) from the baseline DBP change (%) from the baseline
Mauchly’s Time Time*genotype genotype Mauchly’s Time Time*genotype genotype
ORM1 A113G 0.004 0.000 0.748 0.770 0.000 0.000 0.258 0.096
ABCC2 C3972T 0.006 0.000 0.262 0.162 0.000 0.000 0.067 0.018*
ABCC2 G1249A 0.005 0.000 0.795 0.370 0.000 0.030 0.975 0.144
SLCO1B3 T334G 0.001 0.000 0.842 0.995 0.000 0.000 0.431 0.634
ABCG2 C421A 0.001 0.000 0.300 0.255 0.000 0.000 0.451 0.896
ABCB1 C3435T 0.001 0.000 0.369 0.375 0.000 0.000 0.372 0.241
*P,0.05;
ORM1, orosomucoid 1; ABCC2, ATP-binding cassette, sub-family C, member 2; SBP, systolic blood pressure; DBP, diastolic blood pressure; Time, the time point in this
study including 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 48 h after taking telmisartan.
doi:10.1371/journal.pone.0070341.t005
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and the frequency of the allele ORM1*S was lowering from 31% to
19% when presented in central Asia towards the Southeast [38].
The ORM1*S allele frequency in the present study was within
these ranges among the populations of Asia. Different populations
may possess various genetic backgrounds, which would cause the
variability of PKs or even PDs of the substrates. As shown in
Table 2, the MAF of ABCC2 C3972T and G1249A, ABCB1
C3435T, SLCO1B3 T334G almost be similar in three main
populations. While the frequencies of the alleles ABCC2 -24T,
ABCG2 421G shown a apparent decrease in ASW population.
Thus, we speculated that the PKs of Telmisartan in West may
differ from Asia, which was supported the conclusion that after a
high dose of telmisartan, the drug was eliminated faster in
Caucasian than in Chinese subjects [4–5].
However, some shortcomings existed in our study. First, the
subjects in our trial were young and healthy males, with well self-
regulation ability on the BP fluctuations and their body’s
regulation ability may conceal the BP change to some degree.
Second, for the BP value was fluctuated in a day, and the time
showed a significant impacts on the BP change(%) from the
baseline(Table 5). So in this study, there was no enough data to
value the actual antihypertensive pharmacodynamics among the
genotypes if just compare the BP change via took the pre-dose BP
as baseline merely. We should monitor the volunteer’s blood
pressure at the same time on another day when taking no
telmisartan, in order to remove the diurnal variation within
individuals. Third, the number of participants was not large
enough to get a convincing conclusion. For example, there was no
subject with homozygous ORM1 113GG genotypes enrolled in this
trial for us to explore the influence of the genotype 113GG.
Hence, this conclusion needs to be identified in a larger population
in the further research, especially in the hypertensive.
To explore the possible reasons for the metabolism variation,
can benefit us to improve the efficiency of telmisartan. Our study
showed that the polymorphisms of ORM1 A113G can absolutely
affected the disposition of telmisartan in vivo after administration,
as well as the SNPs of ABCC2 C3972T. It is a new discovery would
help us to understanding the mechanism of the noteworthy
disposition difference after telmisartan taken, however it need
further researches to confirm in a large scale population.
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